Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Lexeo Therapeutics, Inc. (LXEO)
NASDAQ:LXEO
RESEARCH TOOLSreports
Holding LXEO?
Track your performance easily
LXEO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$7.47 - $22.33
Previous Close$7.69
Volume1.03M
Average Volume (3M)290.65K
Market Cap
$254.24M
Enterprise Value$107.62M
Total Cash (Recent Filing)$157.02M
Total Debt (Recent Filing)$10.40M
Price to Earnings (P/E)―
Beta1.56
Next Earnings
Mar 17, 2025EPS Estimate
-$0.77Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.71
Shares Outstanding33,061,004
10 Day Avg. Volume786,654
30 Day Avg. Volume290,650
Standard Deviation0.19
R-Squared0.20
Alpha-0.09
Financial Highlights & Ratios
Price to Book (P/B)1.53
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-2.17
Forecast
1Y Price Target
$22.40Price Target Upside187.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Lexeo Therapeutics, Inc. News
Bulls Say, Bears Say
Bulls Say
Financial StabilityLexeo ended Q1 with $195.1 mm in cash, cash equivalents and marketable securities, reflecting a strong financial position.
Regulatory ProgressThe company has initiated formal engagements with the FDA to discuss surrogate endpoints for a future registrational study.
Therapeutic InnovationLX1001 showed a dose-dependent increase in CSF APOE2 with durability up to 12 months.
Bears Say
Clinical TrialsThe study did not show signs that the magnitude of effects can drive cognitive benefit in treated patients, and a larger study would be required to evaluate cognitive benefits.
Drug Development ChallengesThe negative stock reaction is likely due to the implications of adding a higher third dose level to the trial, which delays advancement with expanded treatment of more patients at an optimal dose level.
Financial PerformanceOpEx came in above projections, reducing the price target from $22 to $20.
---
Ownership Overview
0.61% Insiders
11.65% Mutual Funds
5.24% Other Institutional Investors
77.12% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
LXEO FAQ
What was Lexeo Therapeutics, Inc.’s price range in the past 12 months?
Lexeo Therapeutics, Inc. lowest stock price was $7.47 and its highest was $22.33 in the past 12 months.
What is Lexeo Therapeutics, Inc.’s market cap?
Currently, no data Available
When is Lexeo Therapeutics, Inc.’s upcoming earnings report date?
Lexeo Therapeutics, Inc.’s upcoming earnings report date is Mar 17, 2025 which is in 122 days.
How were Lexeo Therapeutics, Inc.’s earnings last quarter?
Lexeo Therapeutics, Inc. released its earnings results on Nov 13, 2024. The company reported -$0.89 earnings per share for the quarter, missing the consensus estimate of -$0.678 by -$0.212.
Is Lexeo Therapeutics, Inc. overvalued?
According to Wall Street analysts Lexeo Therapeutics, Inc.’s price is currently Undervalued.
Does Lexeo Therapeutics, Inc. pay dividends?
Lexeo Therapeutics, Inc. does not currently pay dividends.
What is Lexeo Therapeutics, Inc.’s EPS estimate?
Lexeo Therapeutics, Inc.’s EPS estimate is -$0.77.
How many shares outstanding does Lexeo Therapeutics, Inc. have?
Lexeo Therapeutics, Inc. has 33,061,005 shares outstanding.
What happened to Lexeo Therapeutics, Inc.’s price movement after its last earnings report?
Lexeo Therapeutics, Inc. reported an EPS of -$0.89 in its last earnings report, missing expectations of -$0.678. Following the earnings report the stock price went down -0.65%.
Which hedge fund is a major shareholder of Lexeo Therapeutics, Inc.?
Among the largest hedge funds holding Lexeo Therapeutics, Inc.’s share is D1 Capital Partners LP. It holds Lexeo Therapeutics, Inc.’s shares valued at 23M.
---
Lexeo Therapeutics, Inc. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.40 (187.92% Upside)
$22.40 (187.92% Upside)
Blogger Sentiment
Bullish
LXEO Sentiment 100%
Sector Average 73%
Sector Average 73%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.0%
Last 30 Days ▲ 14.1%
Last 30 Days ▲ 14.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.37%
12-Months-Change
Fundamentals
Return on Equity
-74.84%
Trailing 12-Months
Asset Growth
195.67%
Trailing 12-Months
Company Description
Lexeo Therapeutics, Inc.
Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
---
LXEO Stock 12 Month Forecast
Average Price Target
$22.40
▲(187.92% Upside)
Technical Analysis
Best Analysts Covering LXEO
1 Year
1 Year Success Rate
0/8 ratings generated profit
1 Year Average Return
-35.20%
reiterated a buy rating 2 days ago
Copying Mani Foroohar's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -35.20% per trade.
---